SEASTAR MEDICAL HOLDING CORP
ICUNASDAQTrading Snapshot
- Day Range
- $3.52 – $3.58
- 52-Week Range
- $2.07 – $7.35
- Volume
- $3.08B
- Avg Volume
- $3.07B
- Shares Outstanding
- 2.8M
- Next Earnings
- Nov 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $615,000
- P/E Ratio
- -0.9
- P/S Ratio
- 5.7x
- EPS (TTM)
- $-3.34
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4113.6%
Why Investors Own ICU
- ✓High-growth profile — revenue up +50.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 59% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SEASTAR MEDICAL HOLDING CORP
ICU
StockOtter · stockotter.spaceAbout SEASTAR MEDICAL HOLDING CORP
SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE ® , an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI)
SeaStar Medical Congratulates H. David Humes, M.D.
Prestigious honor recognizes Dr. Humes' pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE ® for critically ill pediatric patients with acute ki
SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference
DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
Quoin Pharmaceuticals releases a new NETHERTON NOW video featuring Laura Wright-Sexton, MD, who first met her daughter Aminah as a patient in the ICU.
ICU Medical to Participate in Upcoming Investor Conferences
SAN CLEMENTE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the followi
SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript
SeaStar Medical Holding Corporation (ICU) Q2 2026 Earnings Call Transcript